Anakinra Utilization in Refractory Pediatric CAR T-cell Associated Toxicities

Overview

Journal Blood Adv

Specialty Hematology

Date 2022 Apr 8

PMID 35395068

Authors

Caroline Diorio

Anant Vatsayan

Aimee C Talleur

Colleen Annesley

Jennifer J Jaroscak

Haneen Shalabi

Amanda K Ombrello

Michelle Hudspeth

Shannon L Maude

Rebecca A Gardner

Nirali N Shah

Affiliations

Soon will be listed here.

Citing Articles

Novel strategies to manage CAR-T cell toxicity.

Mulvey A, Trueb L, Coukos G, Arber C Nat Rev Drug Discov. 2025; .

PMID: 39901030 DOI: 10.1038/s41573-024-01100-5.

Weal and woe of interleukin-18 in the T cell therapy of cancer.

Kessel C, Rossig C, Abken H J Immunother Cancer. 2025; 13(1.

PMID: 39809514 PMC: 11749219. DOI: 10.1136/jitc-2024-010545.

Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia.

Balestra T, Niswander L, Bagashev A, Loftus J, Ross S, Chen R Leukemia. 2024; 39(3):555-567.

PMID: 39681640 PMC: 11879877. DOI: 10.1038/s41375-024-02493-3.

Immunotherapy-related neurotoxicity in the central nervous system of children with cancer.

He J, Connors J, Meador A, Xu S, Meador H, Jiang H Neuro Oncol. 2024; 27(3):625-643.

PMID: 39535217 PMC: 11889721. DOI: 10.1093/neuonc/noae243.

Macrophage activation syndrome in Sepsis: from pathogenesis to clinical management.

Chen S, Zhang C, Luo J, Lin Z, Chang T, Dong L Inflamm Res. 2024; 73(12):2179-2197.

PMID: 39404874 DOI: 10.1007/s00011-024-01957-7.

References

Locatelli F, Jordan M, Allen C, Cesaro S, Rizzari C, Rao A . Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19):1811-1822. DOI: 10.1056/NEJMoa1911326. View

Kadauke S, Myers R, Li Y, Aplenc R, Baniewicz D, Barrett D . Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. J Clin Oncol. 2021; 39(8):920-930. PMC: 8462622. DOI: 10.1200/JCO.20.02477. View

Pan J, Deng B, Ling Z, Song W, Xu J, Duan J . Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. J Cell Mol Med. 2020; 25(2):1089-1099. PMC: 7812291. DOI: 10.1111/jcmm.16176. View

Goldbach-Mansky R, Dailey N, Canna S, Gelabert A, Jones J, Rubin B . Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med. 2006; 355(6):581-92. PMC: 4178954. DOI: 10.1056/NEJMoa055137. View

Hill J, Seo S . How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood. 2020; 136(8):925-935. PMC: 7441168. DOI: 10.1182/blood.2019004000. View

Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S . Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J. 2021; 19(1):98. PMC: 8240425. DOI: 10.1186/s12969-021-00585-3. View

Lichtenstein D, Schischlik F, Shao L, Steinberg S, Yates B, Wang H . Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021; 138(24):2469-2484. PMC: 8832442. DOI: 10.1182/blood.2021011898. View

Gardner R, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A . Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood. 2019; 134(24):2149-2158. PMC: 6908832. DOI: 10.1182/blood.2019001463. View

Maus M, Alexander S, Bishop M, Brudno J, Callahan C, Davila M . Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. J Immunother Cancer. 2020; 8(2). PMC: 7745688. DOI: 10.1136/jitc-2020-001511. View

10.

Shah N, Highfill S, Shalabi H, Yates B, Jin J, Wolters P . CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. J Clin Oncol. 2020; 38(17):1938-1950. PMC: 7280047. DOI: 10.1200/JCO.19.03279. View

11.

Kaneko N, Kurata M, Yamamoto T, Morikawa S, Masumoto J . The role of interleukin-1 in general pathology. Inflamm Regen. 2019; 39:12. PMC: 6551897. DOI: 10.1186/s41232-019-0101-5. View

12.

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M . Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24(6):739-748. DOI: 10.1038/s41591-018-0036-4. View

13.

Majzner R, Ramakrishna S, Yeom K, Patel S, Chinnasamy H, Schultz L . GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022; 603(7903):934-941. PMC: 8967714. DOI: 10.1038/s41586-022-04489-4. View

14.

Giavridis T, van der Stegen S, Eyquem J, Hamieh M, Piersigilli A, Sadelain M . CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018; 24(6):731-738. PMC: 6410714. DOI: 10.1038/s41591-018-0041-7. View

15.

Verma A, Pai M, Saha S, Bean S, Fralick M, Gibson J . Managing drug shortages during a pandemic: tocilizumab and COVID-19. CMAJ. 2021; 193(21):E771-E776. PMC: 8177913. DOI: 10.1503/cmaj.210531. View

16.

Dreyzin A, Jacobsohn D, Angiolillo A, Wistinghausen B, Schore R, Perez E . Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults. Pediatr Hematol Oncol. 2021; 39(4):370-378. DOI: 10.1080/08880018.2021.1988012. View

17.

Wei S, Gu R, Xu Y, Liu X, Xing Y, Gong X . Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function. Immunotherapy. 2020; 12(14):1047-1052. DOI: 10.2217/imt-2020-0116. View

18.

McNerney K, DiNofia A, Teachey D, Grupp S, Maude S . Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy. Blood Cancer Discov. 2022; 3(2):90-94. PMC: 9245357. DOI: 10.1158/2643-3230.BCD-21-0203. View

19.

Ahmed A, Merrill S, Alsawah F, Bockenstedt P, Campagnaro E, Devata S . Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. PMC: 8054981. DOI: 10.1016/S2352-3026(19)30156-5. View

20.

Hines M, Keenan C, Alfaro G, Cheng C, Zhou Y, Sharma A . Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy. Br J Haematol. 2021; 194(4):701-707. PMC: 8756350. DOI: 10.1111/bjh.17662. View